1 completed, 1 not yet recruiting, 1 recruiting, 1 suspended. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 1, Not yet recruiting 1, Recruiting 1, Suspended 1 |
| Phase 2 | 1 | Completed 1 |
Follow Masitinib (4.5): new trials by email Literature Review of Masitinib (4.5) trials Research Report on Masitinib (4.5)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Masitinib in Patients With Mild Alzheimer's Disease Placebo, Masitinib (4.5), Standard of care - Alzheimer Disease | Phase 3 | Not yet recruiting | AB Science | 600 | 2026-06-01 | 2025-10-03 |
| Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis Placebo, Masitinib (4.5) - Progressive Multiple Sclerosis | Phase 3 | Suspended | AB Science | 800 | 2022-06-28 | 2026-05-06 |
| Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients Masitinib (6.0), Riluzole, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Recruiting | AB Science | 495 | 2021-02-02 | 2025-09-12 |
| Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Masitinib (4.5), Riluzole, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Completed | AB Science | 394 | 2013-04-01 | 2023-09-29 |
Amyotrophic Lateral Sclerosis (2) · Alzheimer Disease (1) · Motor Neuron Disease (1) · Multiple Sclerosis, Chronic Progressive (1)
AB Science (4)
Spain (4) · France (3) · Greece (2) · Italy (2) · Poland (2) · Russia (2) · Sweden (2) · Ukraine (2) · Belgium (1) · Denmark (1) · Germany (1) · Israel (1) · Norway (1) · Portugal (1) · Serbia (1)
Albert Ludolph, MD, PhD (1) · Bruno Dubois, MD, PhD (1) · Jesus S Mora, MD (1)